Press releases 27/07/2026

  • Medimaps Group has expanded its partnership with CARPL.ai, bringing TBS Reveal™ onto CARPL’s marketplace alongside RBfracture™, giving radiology departments access to both AI applications through a single integration. 
  • TBS Reveal™ and RBfracture™ remain independently developed and regulated products, together supporting bone health from early fracture risk detection through to diagnosis. 

GENEVA, SWITZERLAND — July 27, 2026

Medimaps Group — the creators of TBS® (Trabecular Bone Score®), the global standard in bone microarchitecture assessment — today announced an expanded agreement with CARPL.ai that brings TBS Reveal™, its AI software for opportunistic bone-fragility assessment from routine X-rays, onto CARPL’s marketplace alongside RBfracture™, Radiobotics’ AI-powered trauma-detection solution.

Through a single CARPL integration, radiology departments can now access two Medimaps AI solutions that sit at different points in the same care pathway: TBS Reveal™, which surfaces bone-fragility risk before a first fracture occurs, and RBfracture™, which detects fractures and other trauma-related findings at the point of diagnosis.

“Radiology departments shouldn’t need separate integrations for every stage of bone health. With TBS Reveal and RBfracture both available through CARPL, we can meet clinicians at the point where risk is first surfaced and again at the point where a diagnosis is confirmed, all through the systems they already use,” said Gino Fiore, Chief Commercial Officer, Medimaps.

A marketplace built for scale 

CARPL.ai is the world’s largest radiology AI marketplace and enterprise platform, offering more than 300 AI applications from over 100 partners through a single integration, procurement, and monitoring layer. ¹ 

RBfracture™ has been available through CARPL’s marketplace since 2022 and recently supported a national-scale MSK AI deployment with Medica in the UK. ² 

“Healthcare needs AI that’s easy to adopt. That’s exactly what our partnership with Medimaps delivers. By bringing TBS Reveal alongside RBfracture on CARPL.ai, we’re giving providers seamless access to two complementary solutions through a single integration and governance layer. When adoption becomes simple, it has a much better chance of reaching patients.” said Dhruv Sahai, Chief Operating Officer, CARPL.ai. 

What this means for bone health 

This agreement is a step toward Medimaps’ vision to create an era where healthy bones are the norm. 

By making both TBS Reveal™ and RBfracture™ available through the same platform, Medimaps has the opportunity to reach more of the moments where bone health is decided — from an X-ray that may flag a fragility risk, to the read that confirms a fracture. 

The two products remain independently developed and regulated (TBS Reveal™ 

 by Medimaps and RBfracture™ by Radiobotics ), but the agreement reflects how closely the two are working as a single company. 

Through CARPL’s growing marketplace, any radiology department can add either product without a separate integration or procurement process. 

About Medimaps 

Medimaps (Medimaps Group SA) is the creator of TBS™ (Trabecular Bone Score), a global standard in bone microarchitecture assessment. Supported by over 1,600 publications and integrated into clinical guidelines worldwide, TBS™ is an established complement to bone mineral density (BMD) in fracture risk assessment. 

Founded by medical practitioners and clinical researchers, Medimaps brings together world-class science and a genuine passion for bone health. Following its merger with Radiobotics (Radiobotics ApS), an award-winning Danish MedTech company, Medimaps is building a clinical portfolio spanning the MSK care continuum — from TBS Reveal™, opportunistic bone fragility assessment from routine X-rays, to TBS Osteo™, for osteoporosis fracture risk assessment on DXA, to RBfracture™, designed to support emergency and radiology teams with detection of trauma-related findings on X-ray. 

Driven by a shared vision to create an era where healthy bones are the norm, Medimaps is headquartered in Geneva, Switzerland, with offices in Denmark, France and the US. 

Learn more at www.medimaps.ai. 

Media contact 

Elyse Sims, Sr. Director, Global Marketing 
esims@medimapsgroup.com 

About CARPL.ai 

Founded in 2021, CARPL.ai is a global healthcare technology company having the world’s largest radiology AI marketplace and platform offering 300+ applications from 100+ AI partners. With regulatory clearances across the globe, it enables radiologists and researchers to seamlessly build, test, deploy & monitor radiology AI solutions into their clinical practice. CARPL provides a single user interface, a single data channel, and a single procurement channel to bring AI solutions into clinical radiology workflows. 

CARPL has partnerships and integrations with all leading PACS systems which makes it even more seamless for radiology groups and departments to adopt AI. Trusted by leading healthcare organizations worldwide, CARPL serves as the governance layer for responsible, scalable AI adoption in radiology. 

Over the past few years, CARPL has been recognized as the KPMG US Tech Innovator, Economic Times’ Health Tech Startup of the Year, and a YourStory Tech30 pioneer, alongside being handpicked as one of only three Indian AI startups to showcase its platform to Bill Gates. 

Learn more at www.carpl.ai. 

Media contact 

Marketing and Strategy 
shruti.singhal@carpl.ai 

References 

1. CARPL (2026). CARPL.ai raises $10Mn led by IFC to accelerate healthcare AI adoption globally. [online] CARPL.ai. Available at: https://carpl.ai/news/carplai-raises-10mn-led-by-ifc-to-accelerate-healthcare-ai-adoption-globally [Accessed 27 July 2026]. 

2. Radiobotics (2026). Radiobotics and CARPL to support MSK AI deployment at national scale at Medica. [online] Radiobotics. Available at: https://radiobotics.com/press-release/radiobotics-and-carpl-to-support-msk-ai-deployment-at-national-scale-at-medica/ [Accessed 27 July 2026].